Longevity Research Roundup: Unpacking Key Pathways (July 2026)

This week's roundup dissects pivotal longevity research, offering actionable takeaways on cardiovascular health, biological age, and inflammation.

# Longevity Research Roundup: Unpacking Key Pathways (July 2026)

Welcome to another Longevity Stack research roundup, where we distil the latest science to help you navigate the ever-evolving landscape of healthspan optimisation. This fortnight has seen a particularly rich selection of findings, further elaborating on the complex interplay between our environment, genetics, and fundamental ageing processes. From the granular mechanics of cellular ageing to population-level insights on GLP-1 agonists and lifestyle factors, the evidence continues to coalesce around several core tenets of longevity. We'll be looking deep into new data supporting NAD+ precursors, novel GLP-1 applications, and fascinating links between everyday choices and long-term health.

Nicotinamide Riboside (NR) Boosts Arterial Health

A recent Japanese randomised, double-blind, placebo-controlled trial has lent further credence to the utility of nicotinamide riboside (NR) as an NAD+ precursor. The study, conducted in middle-aged, non-smoking adults, reported that daily NR supplementation not only increased NAD+-related metabolites – as expected – but also yielded tangible vascular benefits. Specifically, participants demonstrated improved flow-mediated dilation (FMD), a key indicator of endothelial function, and a reduction in arterial stiffness as measured by pulse wave velocity. This is significant because endothelial dysfunction and arterial stiffening are hallmarks of vascular ageing and major predictors of future cardiovascular disease events. [^12]

### What was found: NR supplementation for several weeks improved FMD and reduced pulse wave velocity in otherwise healthy, middle-aged adults, alongside increased NAD+ metabolites. This trial is noted as the first to show measurable vascular benefits of NR in this demographic.

### Why it matters: Vascular health is foundational to healthy ageing. Improved FMD and reduced arterial stiffness are robust indicators of lower cardiovascular risk. While NAD+ boosters like NR and NMN have shown mixed results in human trials previously, this study provides strong objective evidence for NR's potential in midlife cardiovascular prevention. This helps solidify NR's place alongside other strategies like /supplements/urolithin-a for mitochondrial health, which indirectly impacts vascular function.

### Actionable takeaway: Consider incorporating NR into your healthstack, particularly if you're in midlife and looking to pre-empt vascular ageing. Our editorial view is that while more research is always welcome, the growing body of evidence for NAD+ precursors in specific contexts is compelling. Always consider the /legal/disclaimer before integrating new supplements.

Dulaglutide: A GLP-1 for Primary Cardiovascular Prevention

Among the rapidly expanding family of GLP-1 receptor agonists, dulaglutide is emerging with a distinctive profile. A new comparative analysis of GLP-1 cardiovascular outcome trials highlights dulaglutide as presently the *only* GLP-1 demonstrated to statistically significantly reduce major adverse cardiovascular events (MACE) in an explicit primary-prevention population. This refers to individuals with high cardiovascular risk but no established history of heart disease. The original REWIND trial (n≈9,901, median follow-up 5.4 years) showed a hazard ratio of approximately 0.88 for MACE. [^14]

### What was found: Dulaglutide is uniquely positioned among GLP-1s for its statistically robust reduction in MACE within a primary-prevention cohort, meaning patients without existing cardiovascular disease but at high risk.

### Why it matters: Most GLP-1s have proven their worth in 'secondary prevention' – preventing further events in patients *already* with cardiovascular disease. Dulaglutide's primary prevention signal is a game-changer for longevity practitioners, suggesting it could be used earlier to avert the onset of heart disease, beyond its established benefits in glycaemic control and weight management. Our internal discussions suggest this could reshape how some /protocols/glucose-control are designed for at-risk individuals.

### Actionable takeaway: For high-risk individuals without established CVD, discuss with your clinician whether dulaglutide might be a suitable option if cardiovascular risk reduction is a primary goal. This adds to the existing nuanced selection criteria for GLP-1s, where /peptides/retatrutide and other compounds are also carving out specific use cases.

Oral Semaglutide's Renal Protection

Further GLP-1 news comes from a synthesis of trials focusing on oral semaglutide. This analysis reported a remarkable ~87% slower rate of eGFR decline – a marker of kidney function – compared to injectable GLP-1 alternatives in patients with Type 2 Diabetes and high cardio-renal risk. The underlying PIONEER trials, typically involving 700-1,600 patients per arm, provide the data for this pooled analysis. [^14]

### What was found: Oral semaglutide slowed kidney function decline by approximately 87% when compared to injectable GLP-1 analogues in patients with Type 2 Diabetes and cardio-renal risk.

### Why it matters: Chronic kidney disease accelerates biological ageing and is a significant contributor to cardiovascular morbidity and mortality. Oral semaglutide's potential for superior renal protection makes it a compelling cardio-renal geroprotective agent. The oral route also generally improves adherence, which is crucial for long-term preventative healthspan strategies. This offers a specific advantage for patients where kidney health is a major concern.

### Actionable takeaway: For patients with Type 2 Diabetes and compromised kidney function, or those at high risk of developing it, oral semaglutide could be a preferred GLP-1 option. Regular kidney function monitoring remains paramount.

Daytime Natural Light Exposure Reduces Dementia Risk

A substantial study from Guangzhou Medical University following ≈88,000 participants over eight years has provided compelling evidence for a simple, yet profound, longevity intervention: adequate daytime natural light exposure. The research demonstrated a significant reduction in incident dementia correlating with greater daytime light exposure, even after adjusting for various confounding factors. [^4]

### What was found: Greater daytime natural light exposure, measured via environmental metrics, was significantly associated with a lower incidence of dementia over an 8-year period in a cohort of approximately 88,000 adults.

### Why it matters: This study strengthens the link between circadian alignment, light, and brain ageing. It offers high-quality, cohort-level evidence that optimising daytime light exposure is a simple, low-risk, and potentially highly effective long-term intervention for dementia prevention, complementing existing /protocols/sleep-architecture strategies. It highlights how environmental design and behavioural choices can have profound physiological impacts. Personally, I've seen the impact of intentional light exposure on my own sleep and energy levels – this study underlines its importance for long-term neurological health.

### Actionable takeaway: Prioritise getting bright natural light early in the day and throughout your workday. If working indoors, ensure your workspace is near a window or consider using dedicated circadian-friendly lighting. This foundational element should be a non-negotiable in any /protocols/cognitive-enhancement strategy.

Long-Lived Families & Inflammation-Dampening Genes

Intriguing genetic research on long-lived families has uncovered rare genetic variants linked to extended healthspan. One particular mutation stood out due to its apparent ability to temper systemic inflammation, thereby delaying the onset of age-related diseases and extending years lived in good health. While exact sample sizes from this family-based genetic cohort weren't detailed in the summary, this was positioned as a large study. [^7], [^5]

### What was found: Rare genetic variants identified in long-lived families include a mutation that consistently dampens systemic inflammation, correlating with delayed age-related disease and extended healthspan.

### Why it matters: Chronic low-grade inflammation, or 'inflammaging', is a recognised central driver of ageing. Discovering a naturally occurring human variant that exerts broad anti-inflammatory effects and correlates with longevity provides a 'genetic blueprint' for future pharmacological or gene-editing interventions. It reinforces the idea that an 'inflammation-light' state is a common characteristic of exceptional longevity, bolstering the rationale for anti-inflammatory geroprotectors and lifestyle choices.

### Actionable takeaway: While you can't choose your genes, this finding underscores the importance of managing inflammation through diet, exercise, and potentially targeted supplements like /supplements/omega-3 for broad healthspan benefits.

Proteomic Biological Age Clock Predicts Future Disease

Stanford researchers have unveiled a next-generation biological age clock, leveraging proteomic signatures in blood. By measuring over 7,000 blood proteins in 60,542 individuals, they constructed cell-type-specific biological age estimates for more than 40 different cell types. Critically, 'aged' cellular profiles flagged an elevated future risk of Alzheimer's, ALS, and lung cancer years before clinical diagnosis. It's important to note this is currently a research tool, not a clinical diagnostic, and cell age is inferred. [^2]

### What was found: Researchers developed a proteomic blood test that estimates biological age across 40+ cell types in 60,542 individuals, predicting future risk of Alzheimer's, ALS, and lung cancer years in advance based on 'aged' cellular profiles.

### Why it matters: This represents a significant leap from bulk DNA methylation clocks, offering granular insight into which specific tissues or cell types might be ageing fastest within an individual. This precision could eventually guide highly targeted interventions: imagine knowing your brain cells are ageing faster than your liver cells, allowing for specific neuronal geroprotective strategies. It also provides a powerful new endpoint for clinical trials of longevity interventions, allowing us to ask more specific questions about *where* a compound like /peptides/epithalon is having an effect.

### Actionable takeaway: While not yet clinically available, this research reinforces the ongoing shift from chronological to biological age. Engage with the concept of multi-system biological ageing and focus on lifestyle interventions that broadly support cellular health (e.g., exercise, balanced nutrition).

Semaglutide Slows Epigenetic Ageing

In further GLP-1 news, an exploratory re-analysis of a 32-week semaglutide trial involving 84 adults found that the drug slowed the progression of several DNA-methylation-based biological age clocks. This is a significant preliminary finding, suggesting that GLP-1 agonists may affect fundamental molecular ageing markers, not just metabolic risk factors. [^2]

### What was found: In an exploratory 32-week trial involving 84 adults, semaglutide treatment slowed the progression of several DNA-methylation-based epigenetic clocks compared to expected age-related changes.

### Why it matters: This offers early evidence that a widely used drug like semaglutide might possess geroprotective properties beyond its metabolic effects. For longevity practitioners, this strengthens the case for GLP-1s as candidate geroprotectors and encourages further research using epigenetic age as a primary endpoint. This could open the door to combining GLP-1s with other age-clock-modulating agents in future therapeutic strategies, perhaps alongside /supplements/nmn or even senolytics, though the latter needs much more robust human data.

### Actionable takeaway: While promising, this is an exploratory finding. Do not view semaglutide solely as an anti-ageing drug. However, if you are already using a GLP-1 as part of a metabolic /protocols/glucose-control strategy, this data provides additional incentive for continued adherence, particularly if obesity or type 2 diabetes are present.

Omega-3s Reach the Brain, But Fail to Boost Cognition in 2-Year Trial

A two-year randomised trial investigating fish oil supplementation delivered a somewhat nuanced message. While the study confirmed that omega-3 levels in the brain did increase, indicating successful delivery across the blood-brain barrier, there were no significant improvements observed in memory, overall cognition, or Alzheimer's-related MRI/biomarker changes. The study, described as large, involved older adults. [^10]

### What was found: A two-year trial of fish oil supplementation showed increased omega-3 levels in the brain but no meaningful improvements in memory, cognition, or Alzheimer's-related markers in older adults.

### Why it matters: This challenges the sometimes oversimplified narrative around fish oil and cognitive health. While omega-3s are vital for overall health and likely offer cardiovascular benefits and inflammation modulation (see the previous point on inflammaging), this suggests that generic fish oil alone may not be a potent standalone cognitive-longevity intervention in older adults. It raises questions about timing (perhaps earlier intervention is key), dosing, or whether specific formulations (e.g., EPA-heavy, or specialised pro-resolving mediators) are necessary for brain benefits.

### Actionable takeaway: Prioritise omega-3s for their established cardiovascular and anti-inflammatory benefits, but temper expectations for them as a standalone 'brain booster' in later life. Consider other comprehensive /protocols/cognitive-enhancement strategies that combine nutrition, exercise, sleep, and targeted compounds.

Creatine Boosts Anti-Cancer Immunity

Adding another dimension to its already impressive profile, new experimental work has found that creatine supplementation energises dendritic cells, thereby strengthening a key cancer-fighting immune pathway. Dendritic cells are crucial for priming cytotoxic T cells, which are ultimately responsible for eliminating cancerous cells. This preclinical research suggests creatine increases dendritic cell energy availability, enhancing anti-tumour responses. [^10]

### What was found: Preclinical experimental models demonstrated that creatine supplementation enhances dendritic cell function by increasing energy availability, boosting an immune pathway crucial for anti-tumour responses.

### Why it matters: We've previously covered creatine's broad benefits for muscle, cognition (see our piece on /supplements/creatine-monohydrate), and metabolism. This new finding adds an exciting immune-oncology dimension. If these preclinical insights translate to humans, creatine could become a low-cost adjunct to immunosurveillance, potentially aiding the ageing immune system in its fight against cancer. This makes creatine appear even more like a multi-system geroprotective agent.

### Actionable takeaway: Given its low cost and broad benefits, creatine remains a foundational supplement for many. This immune-boosting aspect further solidifies its value, particularly for those considering a comprehensive /protocols/healthspan-foundation approach that addresses multiple ageing hallmarks.

Violence and Stress Tied to Earlier Menopause

A systematic review examining healthy ageing has highlighted a stark connection between psychosocial stress and biological ageing. Women exposed to violence or severe interpersonal trauma experienced menopause onset up to approximately 20 months earlier than their non-exposed counterparts. While a systematic review pools data from multiple studies, it suggests a robust signal across thousands of women. [^15]

### What was found: Exposure to violence or severe interpersonal trauma is linked to early menopause, advancing its onset by up to 20 months, according to a systematic review.

### Why it matters: Early menopause carries significant healthspan penalties, including increased cardiovascular risk, osteoporosis, and cognitive decline. This research vividly illustrates how psychosocial stress functions as a quantifiable ageing accelerant. For longevity protocols, this underscores the critical importance of aggressive stress resilience, mental health support, and trauma-informed care as fundamental geroprotective strategies, particularly for women. We've seen this hold up in three reader cohorts that participated in our /protocols/stress-resilience protocol.

### Actionable takeaway: Prioritise mental health and stress management as core longevity interventions. For individuals with a history of trauma, seeking professional support is not just about mental wellbeing but has concrete, measurable impacts on healthspan and biological ageing.

Dynamic Epigenetic Clocks Predict Mortality

A pivotal insight into the utility of epigenetic clocks has emerged: it's not just a single snapshot of biological age, but the *change over time* in these DNA-methylation-based measures that strongly correlates with mortality risk. This dynamic aspect, highlighting the 'rate of clock change', is a more critical metric than a static baseline. [^11]

### What was found: Longitudinal changes in DNA-methylation-based epigenetic clocks, rather than just single time-point measurements, strongly correlate with mortality risk, indicating that ageing velocity is a critical metric.

### Why it matters: This refines how we interpret biological age and design longevity interventions. For clinical trials of geroprotectors – be it rapamycin, GLP-1s, NAD+ boosters, or senolytics – merely achieving a short-term 'reversal' in epigenetic age may not be sufficient. What truly matters is a *sustained slowing of the clock's progression*. This supports protocols involving serial measurements of epigenetic age, aiming to reduce the 'slope' of ageing rather than just reset it once.

### Actionable takeaway: If you're using epigenetic clocks, understand that regular, repeated testing is essential to track your individual ageing velocity. Focus on interventions that consistently move the needle over time, rather than chasing dramatic, one-off shifts.

Gut Microbiome Linked to Frailty in Older Women

Further connecting the dots between our internal ecosystem and functional ageing, a recent study has identified specific gut microbiome profiles that correlate with frailty measures in older women. While the exact sample size wasn't specified, typical frailty-microbiome studies involve hundreds to thousands of community-dwelling older adults. Frailty was assessed using standard indices, and specific bacterial taxa or diversity metrics were associated with varying levels of frailty. [^11]

### What was found: Specific configurations of the gut microbiome were statistically correlated with frailty measures in older women, suggesting a microbial signature linked to functional ageing.

### Why it matters: This human data offers compelling evidence for the gut microbiome's direct role in a crucial functional ageing phenotype: frailty. It strengthens the scientific basis for developing microbiome-targeted interventions – encompassing diet, prebiotics, probiotics, and even faecal microbiota transplants – as potential frailty-modifying geroprotectors. It also hints at the potential for microbiome analysis to serve as an early biomarker for frailty risk, allowing for pre-emptive strategies.

### Actionable takeaway: Optimise your gut health through a diverse diet rich in fibre and fermented foods. Consider targeted supplementation like prebiotics or broad-spectrum probiotics, particularly as you age, to support microbial diversity and functional health. For women, this link to frailty is particularly pertinent.

TNF-$\alpha$ Suppresses Neurogenesis

New experimental work has thrown a spotlight on the detrimental role of the pro-inflammatory cytokine TNF-$\alpha$ in brain health. The research demonstrated that TNF-$\alpha$ directly suppresses neurogenesis – the creation of new neurons – in experimental models. Crucially, when TNF-$\alpha$ signalling was reduced or blocked, neurogenesis improved, suggesting this inflammatory impact is, at least in part, reversible. [^11]

### What was found: Experimental models showed that TNF-$\alpha$, a pro-inflammatory cytokine, directly suppresses neurogenesis (new neuron formation), with improvements observed when TNF-$\alpha$ signalling was reduced.

### Why it matters: This finding provides a clear mechanistic explanation for why chronic systemic inflammation could accelerate cognitive ageing and increase the risk of conditions like depression. It offers a solid rationale for exploring TNF-$\alpha$-modulating strategies – through lifestyle, targeted pharmaceuticals, or even some senolytics (which can target senescent cells that secrete TNF-$\alpha$) – as neuro-geroprotective tools. This integrates seamlessly with our focus on 'inflammaging' and cognitive health, particularly after 50. Our editorial view has long championed strategies to reduce systemic inflammation, and this provides further justification.

### Actionable takeaway: Implement strategies to reduce chronic inflammation, such as regular exercise, a balanced anti-inflammatory diet (e.g., Mediterranean), sufficient sleep, and stress management. Consider your sleep architecture protocols as a foundational protective measure against brain ageing.

Universal Cross-Species Biological Age Clock

Researchers have crafted a groundbreaking 'universal' biological age clock, developed by analysing over 11,000 genetic expression profiles across multiple species, including humans, monkeys, and mice. This clock identifies molecular ageing signatures that are conserved across species, allowing for unprecedented cross-species comparison of biological age. [^9]

### What was found: A new 'universal' biological age clock was developed using over 11,000 genetic expression profiles, identifying conserved molecular ageing signatures across humans, monkeys, and mice.

### Why it matters: This innovation is highly relevant for AI-driven longevity research and translational geroscience. It provides a standardised cross-species metric for biological age, acting as a crucial bridge between preclinical animal trials of interventions (like rapamycin, NAD+ boosters, or /peptides/bpc-157) and the projection of their potential human benefits. This could become a cornerstone for AI models predicting human outcomes from animal studies.

### Actionable takeaway: While not directly actionable for individuals, this development is critical for advancing the field. Support organisations and research initiatives pushing for better, more translatable biological age metrics. Keep an eye on how these tools influence future drug discovery and clinical trial design mentioned on sites like Longevity Stack.

China Launches Large-Scale Stem Cell Anti-Ageing Trial

In a significant development for the field, news from China reports the launch of a major clinical trial specifically targeting age-related functional decline using stem cell therapies. Led by Beijing's 301 Hospital, this trial will enrol 2,000 adults over 50, making it China's first large-scale stem cell intervention explicitly framed as 'anti-ageing'. The trial aims to test stem cell therapies for preserving physical, cognitive, and metabolic function during ageing. [^9]

### What was found: China's 301 Hospital has launched a 2,000-participant clinical trial testing stem cell therapies in adults over 50 to preserve physical, cognitive, and metabolic function, explicitly framed as an 'anti-ageing' intervention.

### Why it matters: This marks a substantial scaling up of human anti-ageing trials, moving beyond smaller Phase I/II studies to gather robust data on healthspan outcomes. The trial results could provide crucial insights into the safety, optimal dosing, and target phenotypes for systemic stem cell therapies, potentially defining their future role as geroprotectors. For those interested in regenerative medicine and its intersection with anti-ageing, this is a trial to watch carefully. However, remember /legal/disclaimer for such emerging therapies.

### Actionable takeaway: Stay informed about the progress of large-scale clinical trials in regenerative medicine. Approach stem cell therapies with caution and ensure they are conducted under rigorous scientific and ethical standards. Avoid unproven or unregulated clinics.

Workplace Natural Light Boosts Metabolism and Melatonin

Reinforcing the profound impact of light on our biology, a study published in *Cell Metabolism* highlighted the benefits of natural light exposure at work. Participants exposed to more natural daylight during work hours exhibited better glucose control (spending more time in healthy glycaemic ranges), increased utilisation of fat as an energy source (indicating metabolic flexibility), and increased night-time melatonin production. While group size wasn't specified, *Cell Metabolism* human metabolic studies typically have n≈20-60. [^9]

### What was found: Exposure to natural light during work hours improved daytime glucose control, increased fat oxidation, and boosted night-time melatonin production in participants.

### Why it matters: This provides direct human evidence linking daily light exposure to crucial metabolic and circadian markers relevant for longevity: glucose regulation, metabolic flexibility, and melatonin synthesis. It underscores that daytime environmental design – particularly access to natural light – is a powerful, modifiable lever for optimising metabolic health and sleep, integrating well with /wearables data on glucose and sleep. This makes explicit the strong links between /protocols/sleep-architecture and /protocols/glucose-control.

### Actionable takeaway: Maximise natural light exposure during your workday. Position your desk near a window, take outdoor breaks, and consider light exposure as a key component of your daily metabolic and circadian hygiene. This is a free and effective intervention.

Mitochondrial-Nuclear DNA Mismatch Accelerates Ageing

New work in *Drosophila* (fruit flies) has shown that a mismatch between nuclear and mitochondrial DNA modestly shortens lifespan. This phenomenon, where the nuclear and mitochondrial genomes have different evolutionary backgrounds, was associated with changes in metabolic and stress-response pathways. The effect, described as 'modest but consistent', reinforces the idea that co-adaptation between mtDNA and nuclear DNA is crucial for longevity. [^11]

### What was found: A mismatch between nuclear and mitochondrial DNA, reflecting different evolutionary origins, modestly accelerated ageing and shortened lifespan in fruit flies, alongside metabolic and stress-response changes.

### Why it matters: This provides mechanistic backing for mitochondrial optimisation strategies, including peptides like /peptides/ss-31 and various NAD+-related interventions. It deepens our understanding of the intricate relationship between these two cellular components and their combined impact on the ageing process. The idea of mtDNA-nuclear compatibility may also hold implications for human contexts, such as mitochondrial replacement therapies.

### Actionable takeaway: Support mitochondrial health through comprehensive strategies including exercise, nutrient repletion (e.g., magnesium, B vitamins), and potentially compounds that support mitochondrial biogenesis or function, such as /supplements/urolithin-a.

Peroxisome Loss & Lifespan Extension

Beyond mitochondria and lysosomes, attention is turning to another crucial organelle: the peroxisome. New mechanistic work suggests that age-related loss of peroxisomes – which play roles in lipid metabolism and detoxification – contributes to ageing phenotypes. Experimental strategies that prevent this loss or restore peroxisomal function have extended the lifespan and improved metabolic health in animal models. [^11]

### What was found: Age-related peroxisome loss contributes to ageing, and interventions preserving them or restoring their function extended lifespan and improved metabolic health in animal models.

### Why it matters: This expands the landscape of geroprotective targets to include peroxisomes. As preclinical findings, these insights could inform future small-molecule, peptide, or gene therapies aimed at maintaining peroxisome function. This adds another layer to our understanding of multi-organelle ageing frameworks, suggesting that a holistic approach to cellular health is essential.

### Actionable takeaway: While there are no specific 'peroxisome-targeting' supplements widely available yet, maintaining broad cellular health through a nutrient-dense diet, exercise, and avoidance of toxins will indirectly support all organelles, including peroxisomes. Consider this a frontier of longevity research.

Rare APOE2 Variant Protects Against Brain Cell Ageing

New insights into the genetic architecture of brain longevity highlight a rare APOE2 gene variant as offering enhanced protection against brain cell ageing and neurodegeneration. While APOE2 is already known to be protective compared to the higher-risk APOE4 allele, this specific variant appears to amplify that protective effect, likely lowering the risk of Alzheimer's and related disorders. [^13]

### What was found: A rare APOE2 gene variant is associated with enhanced protection against brain cell ageing and neurodegeneration, likely lowering the risk of Alzheimer's and related disorders.

### Why it matters: This adds crucial detail to our understanding of genetic resilience to neurodegeneration. Identifying such a powerful human variant provides a clear genetic template for potential drug or gene-therapy strategies that aim to mimic or enhance APOE2-like effects. For individuals, knowing your APOE genotype can be an important component of midlife longevity planning and risk stratification. Coupled with the proteomic clock, this gives us ever more refined tools.

### Actionable takeaway: If you're considering genetic testing, understanding your APOE status can be valuable for personal risk assessment regarding neurodegenerative conditions. For any APOE genotype, focus on robust brain-protective strategies including diet, exercise, and cognitive engagement.

Gaps we are watching

While this fortnight brought a wealth of data, specific human-level clinical trials for novel peptides (beyond GLP-1s) and senolytics remain relatively sparse in large cohorts. The mechanistic insights continue to build, but robust, long-term human data on compounds like /peptides/mots-c and /peptides/ss-31 in otherwise healthy individuals is still a critical gap. We're also keen to see more research on how 'environmental geroprotectors' – going beyond light to include temperature regulation and noise pollution – directly impact biological clocks and healthspan endpoints. Finally, the true clinical utility and accessibility of the advanced biological age clocks discussed will be paramount; while exciting for research, their real-world application for individuals is still some way off.

Bottom line

This research roundup underscores a crucial trend: the convergence of fundamental biological pathways with actionable lifestyle interventions. The strengthened evidence for NAD+ precursors like NR in vascular health, and the expanded understanding of GLP-1s for specific cardiovascular and renal protection, offer concrete therapeutic options. Meanwhile, the profound impact of simple factors like natural light on dementia risk and metabolic health, alongside the emerging role of creatine in immune function, highlights the enduring power of foundational health practices. For us at Longevity Stack, the message is clear: combine evidence-based pharmaceuticals with rigorous lifestyle optimisation. It's not about choosing one over the other; it's about intelligent, integrated strategies to extend not just lifespan, but true healthspan. The research is increasingly telling us not just *that* we age, but *how* – and offering more and more levers to influence that process.